Neutralization of endogenous SDF-1 maintains PB Inc−CD34+ cells in G0 phase
| Incubation time, h . | Anti-SDF-1 treatment . | % of Inc−CD34+ cells in cell cycle phases5-150 . | ||
|---|---|---|---|---|
| G0 . | G1 . | S + G2/M . | ||
| 0 | 28.3 ± 5.8 | 69.4 ± 6.2 | 1.9 ± 0.9 | |
| 48 | − | 15.8 ± 2.45-151 | 78.5 ± 2.9 | 3.9 ± 0.7 |
| + | 29.4 ± 2.15-152 | 68.7 ± 2 | 1.8 ± 0.045-152 | |
| Incubation time, h . | Anti-SDF-1 treatment . | % of Inc−CD34+ cells in cell cycle phases5-150 . | ||
|---|---|---|---|---|
| G0 . | G1 . | S + G2/M . | ||
| 0 | 28.3 ± 5.8 | 69.4 ± 6.2 | 1.9 ± 0.9 | |
| 48 | − | 15.8 ± 2.45-151 | 78.5 ± 2.9 | 3.9 ± 0.7 |
| + | 29.4 ± 2.15-152 | 68.7 ± 2 | 1.8 ± 0.045-152 | |
PB CD34+ cells purified immediately after density gradient separation (Inc−) were incubated (1 × 105 cells/mL) in a serum-free Stemα-A medium for 48 hours. The role of autocrine/paracrine SDF-1 in the cell cycle was evaluated by adding an anti–SDF-1 neutralizing antibody (10 ng/mL) to the culture. Cells were harvested after 0 and 48 hours, counted, and dually stained with PI and anti-Ki67-FITC mAb before flow cytometry analysis.
Based on 5 independent experiments.
P = .001 versus 0 hours.
P = .001 versus untreated cells.